Literature DB >> 581114

Serum somatomedin activity measured as sulphation factor in peripheral, hepatic and renal veins of patients with alcoholic cirrhosis.

R M Schimpff, D Lebrec, M Dannadieu, A M Repellin.   

Abstract

Serum somatomedin (SM) activity, measured as sulphation factor on chick embryo cartilage, and growth hormone (GH) levels were measured in peripheral, hepatic and renal veins of 23 patients with a alcoholic cirrhosis. SM activity (mean +/- SEM) was 0.65 +/- 0.05 U/ml in peripheral vein, 0.59 +/- 0.04 U/ml in hepatic vein, and 0.74 +/- 0.07 U/ml in renal vein. Mean GH levels were respectively 2.8, 2.5 and 3.1 ng/ml. Compared to peripheral vein, SM increase in renal vein was 19% (P less than 0.05). Serum SM activity was significantly lower in 13 patients with alcoholic hepatitis associated with cirrhosis than in other 10 patients (P less than 0.02 in hepatic blood and P less than 0.05 in peripheral blood). The decrease of SM activity seems related to cytolysis and hepato-cellular insufficiency. At last, in patients with alcoholic hepatitis, SM activity was lower in the hepatic vein than in the peripheral vein (P less than 0.05). The cause of this difference remains under discussion, no SM inhibitors being found in the serum samples used in this study.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 581114     DOI: 10.1530/acta.0.0880729

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  3 in total

1.  Serum insulin-like growth factor II in chronic liver disease.

Authors:  T Hayakawa; T Kondo; T Shibata; M Kitagawa; H Ono; Y Sakai; K Kato; N Katada; Y Sugimoto; M Takeichi
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

2.  Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis.

Authors:  E Cantrill; M Murray; I Mehta; G C Farrell
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

3.  IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand.

Authors:  Lucia Guerra-Menéndez; Maria C Sádaba; Juan E Puche; Jose L Lavandera; Luis F de Castro; Arancha R de Gortázar; Inma Castilla-Cortázar
Journal:  J Transl Med       Date:  2013-10-25       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.